Myoridge

Myoridge is a Japan-based startup in the Health Care industry, founded in 2016. The company specializes in culture media and cells, offering custom culture media for cell therapy and immunotherapy, as well as the development of culture media that amplify or control specific cell functions. Additionally, Myoridge develops and supplies culture media tailored to individual needs, such as growth ability, cost reduction, and storage. Moreover, the company is involved in the development of iPS cells for specific disease models and supports the development of differentiation induction technology for various cells. Their latest feat is the ¥142.36M Venture Round investment at 01 March 2021, with funding from Kyoto University Innovation Capital Co., Ltd and RFI Advisors. Myoridge's slogan "Introducing new cell engineering options to the world through culture media" encapsulates its commitment to advancing cell engineering options in the global arena.